Adenocarcinoma of the stomach, including the gastro-oesophageal junction, is the fifth most common cancer in the world, and is predominantly diagnosed in Eastern Asia. Peak onset of the disease is between 60 and 80 years of age and age-standardised incidence rates of gastro-oesophageal adenocarcinoma are twice as high in males than in females. There is significant geographic variation with age-standardised incidence rates ranging from 3.3 in Western Africa to 35.4 in Eastern Asia for men, and from 2.6 in Western Africa to 13.8 in Eastern Asia for women (<http://ci5.iarc.fr>). A better clinical outcome has been reported for Asians, females and young age ([@bib2]; [@bib18]).

Metastases from gastro-oesophageal adenocarcinoma primarily involve the peritoneal cavity, liver and lymph nodes ([@bib21]; [@bib10]). Metastases to the brain are rare ([@bib35]; [@bib12]) and occur in less than 5% of patients with adenocarcinoma of the upper gastrointestinal tract ([@bib32]; [@bib4]).

The product of the *HER2* gene, a member of the epidermal growth factor (EGF) receptor family, is overexpressed and the gene is amplified in 10--22% of patients with gastro-oesophageal adenocarcinoma, both in Asian and in Caucasian patients. The variability in HER2 positivity reported in different studies can partially be explained by intratumoural heterogeneity, insufficient tissue sampling or inconsistent interpretation criteria ([@bib14]; [@bib15]; [@bib3]; [@bib13]; [@bib16]; [@bib33], [@bib34]; [@bib30]).

In gastric cancer, the ToGa trial has recently established HER2 as a predictive marker for response to the monoclonal anti-HER2 antibody trastuzumab. This trial did not include patients with brain metastases (BMets) ([@bib3]).

Few studies have analysed the clinical significance of HER2 in patients with gastro-oesophageal adenocarcinoma and CNS involvement. In a retrospective cohort of 140 patients with oesophageal cancer, 9 patients developed BMets---5 of them were HER2 positive based on immunohistochemistry (IHC) ([@bib1]). In a small series of 20 patients with BMets of gastro-oesophageal adenocarcinoma, three were HER2 positive based on IHC and fluorescence *in situ* hybridisation (FISH) analysis ([@bib24]). Since patients with HER2 positive breast cancer were reported to develop BMets more frequently and more rapidly than patients with HER2 negative cancers ([@bib23]; [@bib22]), we aimed to establish the frequency of HER2 positivity in patients with brain metastases from gastro-oesophageal adenocarcinoma.

E-cadherin (encoded by the *CDH1* gene), a transmembrane glycoprotein involved in maintaining cell--cell contact, has recently been implicated in mediating BMets. Studies examining BMets tissue from lung cancer ([@bib17]) have reported a frequent loss of E-cadherin expression, suggesting a potential role in BMets development. Since both, loss of E-cadherin expression and mutation (deletion), have been associated with worse prognosis in gastric cancer ([@bib29]; [@bib9]), we also wanted to investigate the relationship between E-cadherin status and its relationship with clinicopathological variables in our study population.

Microsatellite instability (MSI), an alteration caused by genetic and epigenetic inactivation of DNA mismatch repair (MMR) genes is usually related to a loss of function of the MMR enzyme system. In sporadic gastric cancer, MMR deficiency occurs in about 10% of cases and has been linked to a more favourable clinical course ([@bib20]; [@bib33], [@bib34]; [@bib7]). We therefore anticipated MMR deficiency to be a rare event in our study population.

To investigate the status of HER2, E-cadherin, and MSI we established a registry of European and Asian patients with gastro-oesophageal adenocarcinomas who had developed metastases to the brain and/or to the leptomeninges.

Patients and methods
====================

Eligible patients met the following criteria: Histologically confirmed adenocarcinoma of the stomach or oesophagus; availability of a clinical data set as defined in the study protocol; central nervous system (CNS) involvement confirmed by central neuro-radiological or histopathological review (cytology, surgical pathology, or autopsy); in the absence of brain images, the medical reports had to demonstrate conclusive evidence of BMets; availability of tumour tissue (from primary and/or from CNS or visceral metastases) for histological review, assessment of HER2 status, expression of E-cadherin and DNA MMR proteins.

The ethics committee of the Canton of Zurich, Switzerland (KEK-ZH-NR: 201 0-0445) and the ethics committees of all collaborating centres approved the study, which is registered on [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), NCT01456455.

The local investigators collected clinical and follow-up data from medical records either from hospital records or from the patients\' general practitioners. Written informed consent was obtained from all patients alive at the time of their inclusion into the study.

Neuroradiology
--------------

The review was performed by a board certified neuroradiologist specialised in neuro-oncology (BS). The patient\'s neuro-imaging studies, including MRI and CT scans, were analysed on a state of the art PACS (Picture and Archiving Communication System) and categorized according to the presence of CNS metastases as a single lesion, multiple lesions (⩽3 or \>3), and/or as leptomeningeal carcinomatosis (LC). Metastases to the CNS were defined as one or multiple contrast enhancing lesions in the brain, in the lepto- or pachymeninges, or in the ependymal lining of the ventricular system. MRIs were analysed based on standardized sequences that is, axial T1, T2, and FLAIR-weighted series with a slice thickness of 4 mm and 3D contrast-enhanced sequence with 1 mm slice thickness reconstructed in three planes. CT scans included non-contrast and contrast exams with 1 mm slice thickness and with reconstruction of the contrast-enhanced series performed in three planes.

Histopathological assessment
----------------------------

Paraffin blocks and/or unstained slides with sufficient tumour tissue were submitted for central pathology review to the Institute of Surgical Pathology, University Hospital Zurich, Switzerland, where the pathological diagnosis (e.g., the presence of adenocarcinoma) was confirmed either based on the review of glass slides or based on the review of digital slides by the study\'s principal pathologist (ZV).

Histological subtypes and grade of differentiation were determined according to the [@bib19]) and the WHO classification ([@bib5]). Adenocarcinomas were categorised as intestinal, diffuse, or mixed type. Adenocarcinomas with signet-ring cells were classified as diffuse type. All diffuse type cancers were graded as poorly differentiated (G3), whereas intestinal type cancers were graded as well (G1), moderate (G2), or poorly (G3) differentiated.

HER2 immunohistochemistry
-------------------------

HER2 protein was assessed using the FDA-approved ready-to-use antibody, PATHWAY anti-HER2/neu clone 4B5 (Ventana Medical Systems, Basel, Switzerland). The immunohistochemical procedure was carried out using the Leica Bond autostainer (Leica Biosystems, Nunningen, Switzerland) or the Ventana Bench Mark Ultra autostainer.

Scoring was performed in accordance with the guidelines of the ToGA trial ([@bib3]) and the corresponding literature ([@bib26]).

HER2 fluorescence or silver enhanced *in situ* hybridisation
------------------------------------------------------------

All cases tested in Zurich, except for patient 100, and all cases from the Netherlands Cancer Institute (NCI), patients 87--99, were tested using silver enhanced *in situ* hybridisation (SISH). Patient 100 was analysed using FISH.

SISH HER2 analysis
------------------

*HER2* copy number status determined with SISH was performed using a dual probe (INFORM HER2 Dual ISH assay, Ventana Medical Systems, Tucson, AZ, USA, catalog Nr: 780-4332) containing the *HER2* region (17q11.2--q12, directly labelled with black) and the centromeric region of chromosome 17 (17p11.1--q11.1, directly labelled with red). The signals were detected with the UltraView SISH detection kit and the UltraView red ISH detection kit as per instructions by the manufacturer. The *in situ* hybridisation procedure was carried out using the Ventana Benchmark autostainer according to the manufacturer recommendation.

At the NCI, ISH Protease 3 (cat. \#5273331001, Ventana Medical Systems), INFORM HER2 DNA Probe (cat. \#5273439001, Ventana Medical Systems), and Rabbit anti-DNP (cat. \#5273447001, Ventana Medical Systems) were used. Bound probe was visualised using silver deposition (ultraVIEW SISH Detection Kit, Ventana Medical Systems) followed by haematoxylin counterstain.

Scoring of SISH signals followed the guidelines established in the ToGA trial ([@bib3]).

FISH HER2 analysis (case 100)
-----------------------------

Fluorescence *in situ* hybridisation was used to establish the *HER2* copy number status in case 100 as described previously ([@bib31]). The FISH scoring was performed in analogy to the scoring applied for SISH.

In summary, HER2 positive tumours were defined as IHC score 3+ or ISH amplified (FISH or SISH) in at least one probe (primary tumour and/or metastastic lesion).

E-cadherin immunohistochemistry
-------------------------------

E-cadherin IHC was performed using either clone EP700Y (Cell Marque, dilution 1 : 200) and the Ventana Benchmark autostainer or clone NCH-38 (DAKO; Cat. \#M3612, dilution 1 : 50) followed by the UltraView Universal DAB Detection Kit (Ventana Medical Systems).

Any membranous immunoreactivity, irrespective of the number of cells or the intensity, was scored as positive. The absence of membranous immunoreactivity or the presence of cytoplasmic stain only was scored as negative.

DNA MMR proteins IHC
--------------------

Immunohistochemistry for MSH2 (clone 25D12, Novocastra (Biosystems Switzerland, Muttenz, Switzerland), dilution 1 : 100; or Clone G219-1129, Roche Ventana Medical Systems, ready-to-use), MSH-6 (clone 44, Becton Dickinson, Allschwil, Switzerland, dilution 1 : 500; or Clone EP49, Epitomics (LabForce, Nunningen, Switzerland), dilution 1 : 50), MLH1 (clone G168-15, Becton Dickinson, dilution 1 : 100; or clone M1, Roche Ventana Medical Systems, ready-to-use) and PMS2 (clone A16-4, Becton Dickinson, dilution 1 : 300; or Clone EPR3947, Roche Ventana Medical Systems, ready-to-use) was performed using the Ventana Benchmark system or using the OptiView DAB Detection Kit (Ventana Medical Systems) followed by counterstaining with haematoxylin.

Any nuclear staining in the tumour cells was considered as 'positive\'. Complete absence of immunoreactivity in the presence of a positive internal control (lymphocytes) was scored as 'negative\'.

Statistics
----------

Descriptive statistics were calculated for the variables of interest, and stratified by subgroups of HER2 status (positive *vs* negative) and ethnicity (Asian *vs* Caucasian). Overall survival was calculated from initial diagnosis to death or last follow-up. Survival from BMets was calculated from diagnosis of BMets to death or last follow-up. Time to BMets was calculated from initial diagnosis to the diagnosis of BMets. We obtained median survival times and their 95% confidence intervals using the Kaplan--Meier method. Results are presented for all patients as well as for the subgroups by HER2 status. All analyses were conducted with R ([@bib25]). A *P*-value of 0.05 was set as statistically significant.

Results
=======

Patients
--------

A total of 129 patients were included in the registry from 2011 to 2013. Of these, 100 fulfilled the inclusion criteria for this study (see [Appendix](#app1){ref-type="app"}).

Twenty-nine registered patients were excluded because (i) there was no tissue available for confirmation of the diagnosis and further analysis (8), (ii) squamous cell histology (7), (iii) lack of clinical data (11), or (iv) the absence of radiologically or histologically confirmed BMets or LC (3) ([Figure 1](#fig1){ref-type="fig"}).

The median age of the included study patients was 59 years (interquartile range 54--68 years) and 85 (85%) were males, 25 (25%) were of Asian ethnicity and 75 (75%) were Caucasian. Forty-five (45%) tumours were located at the cardia and 53 (53%) were classified as 'non-cardia\' cancers, of which 32 (32%) were located in the lower oesophagus (in two cases the tumour localisation was unknown). In 21 (21%) patients BMets were diagnosed synchronously and in 79 (79%) metachronously.

CNS involvement
---------------

Central nervous system involvement was confirmed in 90 patients by diagnostic imaging or by CNS histology or cytology. For 10 patients, MRI or CT scans were not available for review, however, the provided patient medical reports demonstrated conclusive evidence of BMets. Three patients had to be excluded from further analysis due to diagnostic errors (cerebral embolic infarction in two patients and cerebral hemorrhage in one).

CNS involvement was as follows: BMets (*n*=74, 74%), LC alone (*n*=15, 15%), BMets and LC (*n*=11, 11%). Extracerebral metastases were present in 80% of patients (in 6% no information was available). Four of the thirty-six patients with HER2 positive tumours received trastuzumab for metastatic disease. Patient characteristics are summarised in [Table 1](#tbl1){ref-type="table"}.

Histopathological review
------------------------

Tissue was available from the primary tumour in 75% of all patients; in 13% of the cases, primary tumour tissue and matched tissue from at least one distant metastasis could be analysed (eight metastases from the brain and five metastases from lung, lymph nodes and/or liver). In 23 cases, tissue from one or more metastatic sites was available and in two tumour samples (2%) no precise anatomical location was possible.

Sixty percent of the cancers were intestinal-type, 24% diffuse-type, and 12% were classified as mixed-type. Four percent were adenosquamous carcinomas. Twenty-five percent were moderately differentiated (G2) and 75% were poorly differentiated (G3) ([Table 2](#tbl2){ref-type="table"}).

HER2 status
-----------

Thirty-six (36%) of the cancers were HER2 positive either in the primary tumour or in a metastatic lesion. In 11 cases, the HER2 status was concordant between the primary tumour and matched metastases. In two cases, the primary tumour was HER2 negative and the matched visceral metastases were HER2 positive.

The median time from initial diagnosis to the development of metachronous BMets or LC was 9.9 months (95% CI: 8.5--15.1). Patients with HER2 positive primaries developed BMets/LC within a shorter time than patients with HER2 negative primaries (8.9 months, 95% CI: 4.3--14.7 *vs* 12.7 months, 95% CI: 8.8--17.2, log-rank *P*=0.157, not significant). The median overall survival of all patients was 16.9 months (95% CI: 14.4--20.7); there was no significant difference in survival between patients with HER2 positive tumours (17.4 months, 95% CI: 12.1--26.2) and those with HER2 negative tumours (16.4 months, 95% CI: 14.1--21.0). Median survival for patients with synchronous BMets (*n*=21) was 5.2 months (95% CI: 3.5--16.9) whereas for metachronous BMets (*n*=79) median survival reached 19.0 months (95% CI: 16.4--26.2). The median survival from diagnosis of CNS involvement of all patients was 3.4 months (95% CI: 2.3--4.7); there was no significant difference in survival between patients with HER2 positive tumours (4.2 months, 95% CI 3.4--7.4) and HER2 negative tumours (2.3 months, 95% CI 1.8--4.7) ([Table 3](#tbl3){ref-type="table"}).

E-cadherin status
-----------------

E-cadherin data were available for 98 (98%) cases. Nine (9%) demonstrated a complete loss of E-cadherin immunostaining. There was no discrepancy between matched tissue pairs. Outcome between E-cadherin positive and E-cadherin negative patients was identical.

Expression of DNA MMR proteins
------------------------------

Expression of DNA MMR proteins (MLH1, MSH2, MSH6, and PMS2) was assessed in 99 of 100 cases. Loss of expression of at least one of the proteins was seen in 6%. MLH1 and PMS2 were absent in four cases. MLH1, PMS2, and MSH6 were absent in two cases. Loss of MSH2 was not observed. One of 12 matched tissue pairs showed loss of MLH1 and PMS2 in the cerebral metastasis but not in the corresponding extracerebral tumour, all other pairs showed concordance. There was no difference in outcome between MMR proficient and MMR deficient patients.

Discussion
==========

In the present study, we investigated the frequency of HER2 positivity, E-cadherin status, and DNA MMR protein expression and their relationship with patient outcome in a large cohort of patients with CNS metastases of gastro-oesophageal adenocarcinomas. Brain metastases from upper GI cancer are very rare; therefore, the number of patients collected within our registry is substantial and unlikely to be reproduced in a prospective trial.

In our study cohort of 100 patients, 36% had a HER2 positive tumour. This incidence is higher than the reported proportion of HER2 positivity in gastro-oesophageal adenocarcinoma ([@bib14]; [@bib15]; [@bib3]; [@bib13]; [@bib16]; [@bib33], [@bib34]; [@bib30]). Whether our findings suggest a propensity to develop CNS metastases in this patient subgroup or rather reflects a group of patients who lived long enough to develop BMets remains to be investigated.

In cases where tissue was available from the primary tumour and matched metastases (*n*=13), the HER2 status was concordant except for two cases, which could reflect spatial intratumour heterogeneity ([@bib6]; [@bib27]).

Twenty-six percent of our patients had leptomeningeal carcinomatosis (LC), a disease manifestation that is even rarer than brain metastases. In a large series of gastric adenocarcinoma, LC occurred in 8 of 5618 patients with gastric (0.15%) and 7 of 4361 (0.16%) with oesophageal adenocarcinoma ([@bib11]). In our cohort, LC was not related to HER2 status.

Median survival of all patients was longer than expected for patients with advanced disease. While we did not see any relationship between HER2 status and survival, our cohort of virtually trastuzumab-naïve patients with HER2 positive cancers seems to develop BMets more rapidly than patients with HER2 negative cancers, although the difference was not statistically significant. Similar findings have been reported for breast cancer ([@bib22]). Given the limited number of patients, our observation will need to be confirmed.

The expression of E-cadherin and DNA MMR proteins was similar between primary tumours and CNS metastases and did not influence the clinical course of the disease.

Even though this is the largest cohort reported to date, 100 evaluable patients with gastro-oesophageal adenocarcinomas and CNS involvement are still a relatively small number. A substantial part of the analyses was performed retrospectively and may thus be subject to bias. Some clinical data such as performance status, a major prognostic factor for patients with brain metastases ([@bib28]), were not available for the retrospective part of the study. Furthermore there is no matched control group without BMets, thus we had to compare our results with data from the literature.

All the same, our collaborative study has several important strengths: centralised HER2 status assessment, central histopathology review, and central review of clinical data reduced technical sources of variation. Centralised assessment of the cranial imaging increased the likelihood that CNS involvement was accurately diagnosed. Finally, representation of Caucasian and Asian patients enhances the generalisability of our study findings.

In conclusion, we could show that HER2 is frequently overexpressed and amplified in patients with gastro-oesophageal adenocarcinomas and CNS involvement. HER2-targeted therapies may favourably alter the prognosis of these patients and may prolong the time to involvement of the brain and the meninges.
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###### Patients characteristics

                                         **Total**    **Caucasian**    **Asian**
  ------------------------------------ ------------- --------------- -------------
  Patients (*n*)                            100            75             25
   Age (years) (interquartile range)    59 (54--68)    60 (53--67)    58 (55--68)
   Male/female                             85/15          66/9           19/6
  **Tumour location**                                                
  Non-cardia (including oesophagus)        53/98          35/73          18/25
  Cardia                                   45/98          38/73          7/25
  Not known                                  2              2              0
  **Primary tumour**                                                 
  Resected                                  41             27             14
  Non- resected                             50             43              7
  Not known                                  9              5              4
  **CNS involvement**                                                
  BMets                                     74             56             18
  LC                                        15             12              3
  Both                                      11              7              4
  **BMets**                                                          
  Synchronous                             21/100          19/75          2/25
  Metachronous                            79/100          56/75          23/25
  **Extracerebral metastases**                                       
  Present                                   80             61             19
  Absent                                    14             13              1
  Not known                                  6              1              5
  RT to the brain                           69             50             19

Abbreviations: BMets=brain metastases; CNS=central nervous system; LC=leptomeningeal carcinomatosis; *n*=numbers; RT=radiation therapy.

###### Pathological characteristics

                                  **Total**   **Caucasian**   **Asian**
  ------------------------------ ----------- --------------- -----------
  **Laurén classification**                                  
  Intestinal                         60            48            12
  Diffuse                            24            16             8
  Mixed                              12             7             5
  Adenosquamous                       4             4             0
  **WHO grading**                                            
  2                                25/100         21/75         4/25
  3                                75/100         54/75         21/25
  **HER2 score (IHC and ISH)**                               
  Positive                         36/100         28/75         8/25
  Negative                         64/100         47/75         17/25
  **MMR IHC**                                                
  Deficient                          93            70            23
  Proficient                          6             4             2
  NA                                  1             1             0
  **E-Cadherin IHC**                                         
  Present                            89            67            22
  Loss                                9             7             2
  NA                                  2             1             1

Abbreviations: HER2=human epidermal growth factor receptor 2; IHC=immunohistochemistry; ISH=in situ hybridisation; MMR=mismatch repair proteins; NA=not available; WHO=World Health Organisation.

Laurén classification: [@bib19] and WHO grading: [@bib5].

###### Clinical outcome and HER2 status

  ***n*** **(%)**                         **All**        **HER2 positive**   **HER2 negative**
  ---------------------------------- ------------------ ------------------- -------------------
                                         100 (100)            36 (36)             64 (64)
  **Overall survival (months)**                                             
  Median (95% CI)                     16.9 (14.4;20.7)   17.4 (12.1;26.2)    16.4 (14.1; 21.0)
                                                                                  *P*=NS
  **Survival from Bmets (months)**                                          
  Median (95% CI)                     3.38 (2.30;4.72)    4.16 (3.4;7.4)      2.30 (1.8;4.7)
                                                                                  *P*=NS
  **Time to Bmets (months)**                                                
  Median (95% CI)                     9.93 (8.5;15.05)   8.92 (4.30;14.7)     12.7 (8.8;17.2)
                                                                                  *P*=NS

Abbreviations: BMets=brain metastases; CI=confidence interval; HER2=human epidermal growth factor receptor 2; IHC=immunohistochemistry; ISH=in situ hybridisation; *n*=number; *P*=NS *P*-value not significant.

HER2 assessed with IHC and ISH methods.
